Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M
Department of Neurosurgery, University Hospital of Liège and Cyclotron Research Center, University of Liège, Belgium.
J Nucl Med. 1998 May;39(5):778-85.
This study evaluates the usefulness of PET for the preoperative evaluation of brain gliomas and methods of quantification of PET results.
Fifty-four patients with brain gliomas were studied by PET with 18F-fluorodeoxyglucose (FDG) (n = 45) and/or 11C-methionine (MET) (n = 41) before any treatment. Results of visual analysis, calculation of glucose consumption and five tumor-to-normal brain ratios for both tracers were correlated with two histologic grading systems and with follow-up.
Visual analysis (for FDG) and tumor-to-mean cortical uptake (T/MCU) ratio proved to be the best tools for the evaluation of PET results. Methionine was proven to be better than FDG at delineating low-grade gliomas. Tumor-to-mean cortical uptake ratios for FDG and MET were clearly correlated (r = 0.78), leading to the equation T/MCU(FDG) = 0.4 x T/MCU(MET). We showed a good correlation between FDG PET and histologic grading. MET uptake could not differentiate between low-grade and anaplastic astrocytomas but was significantly increased in glioblastomas. Low-grade oligodendrogliomas exhibited high uptake of FDG and MET, probably depending more on oligodendroglial cellular differentiation than on proliferative potential. Uptake was decreased in anaplastic oligodendrogliomas, probably due to dedifferentiation. Care must be taken with peculiar histologic subgroups, i.e., juvenile pilocytic astrocytomas and oligodendrogliomas, because of a discrepancy between high PET metabolism and low proliferative potential (good prognosis). Both tracers proved useful for the prediction of survival prognosis. Methionine proved slightly superior to FDG for predicting the histologic grade and prognosis of gliomas, despite the impossibility of differentiation between Grades II and III astrocytomas with MET. This superiority of MET could be explained by patient sampling (low number of Grade III gliomas submitted to examination with both tracers). The combination of both tracers improved the overall results compared to each tracer alone.
Both tracers are useful for the prediction of the histologic grade and prognosis. The apparent superiority of MET over FDG could be due to the small number of Grade III gliomas studied with both tracers.
本研究评估正电子发射断层扫描(PET)在脑胶质瘤术前评估中的作用以及PET结果的量化方法。
54例脑胶质瘤患者在接受任何治疗前,用18F - 氟脱氧葡萄糖(FDG)(n = 45)和/或11C - 蛋氨酸(MET)(n = 41)进行PET检查。对两种示踪剂的视觉分析结果、葡萄糖消耗量计算以及五个肿瘤与正常脑比值与两种组织学分级系统及随访结果进行相关性分析。
视觉分析(针对FDG)和肿瘤与平均皮质摄取(T/MCU)比值被证明是评估PET结果的最佳工具。蛋氨酸在区分低级别胶质瘤方面被证明优于FDG。FDG和MET的肿瘤与平均皮质摄取比值明显相关(r = 0.78),得出方程T/MCU(FDG) = 0.4×T/MCU(MET)。我们发现FDG PET与组织学分级之间有良好的相关性。MET摄取不能区分低级别和间变性星形细胞瘤,但在胶质母细胞瘤中显著增加。低级别少突胶质细胞瘤表现出FDG和MET的高摄取,可能更多地取决于少突胶质细胞的分化而非增殖潜能。间变性少突胶质细胞瘤的摄取减少,可能是由于去分化。对于特殊的组织学亚组,即青少年毛细胞型星形细胞瘤和少突胶质细胞瘤,必须谨慎对待,因为PET高代谢与低增殖潜能(良好预后)之间存在差异。两种示踪剂都被证明对生存预后的预测有用。尽管用MET无法区分II级和III级星形细胞瘤,但蛋氨酸在预测胶质瘤的组织学分级和预后方面被证明略优于FDG。MET的这种优势可能是由于患者样本(用两种示踪剂检查的III级胶质瘤数量较少)。与单独使用每种示踪剂相比,两种示踪剂联合使用改善了总体结果。
两种示踪剂都对组织学分级和预后的预测有用。MET相对于FDG的明显优势可能是由于用两种示踪剂研究的III级胶质瘤数量较少。